S&P 500   3,971.27
DOW   32,394.25
QQQ   307.12
Walgreens Boots Alliance: Blue Chip, High-Yield Turnaround Story
Lithium Could Be 2023's Next Big Surprise (Ad)
3 Undervalued Dividend Payers For Volatile Market Conditions
Here’s Why Viking Therapeutics Rose Over 50% on Obesity Drug Data
Lithium Could Be 2023's Next Big Surprise (Ad)
Roku And The 20% Rally That’s About To Start 
3 More Downgrades To Put On Your Buy List 
Nevada Could be the Source for America's Green Future (Ad)
The Bottom Is In For McCormick & Company
Buffett's company owns nearly 24% of Occidental Petroleum
S&P 500   3,971.27
DOW   32,394.25
QQQ   307.12
Walgreens Boots Alliance: Blue Chip, High-Yield Turnaround Story
Lithium Could Be 2023's Next Big Surprise (Ad)
3 Undervalued Dividend Payers For Volatile Market Conditions
Here’s Why Viking Therapeutics Rose Over 50% on Obesity Drug Data
Lithium Could Be 2023's Next Big Surprise (Ad)
Roku And The 20% Rally That’s About To Start 
3 More Downgrades To Put On Your Buy List 
Nevada Could be the Source for America's Green Future (Ad)
The Bottom Is In For McCormick & Company
Buffett's company owns nearly 24% of Occidental Petroleum
S&P 500   3,971.27
DOW   32,394.25
QQQ   307.12
Walgreens Boots Alliance: Blue Chip, High-Yield Turnaround Story
Lithium Could Be 2023's Next Big Surprise (Ad)
3 Undervalued Dividend Payers For Volatile Market Conditions
Here’s Why Viking Therapeutics Rose Over 50% on Obesity Drug Data
Lithium Could Be 2023's Next Big Surprise (Ad)
Roku And The 20% Rally That’s About To Start 
3 More Downgrades To Put On Your Buy List 
Nevada Could be the Source for America's Green Future (Ad)
The Bottom Is In For McCormick & Company
Buffett's company owns nearly 24% of Occidental Petroleum
S&P 500   3,971.27
DOW   32,394.25
QQQ   307.12
Walgreens Boots Alliance: Blue Chip, High-Yield Turnaround Story
Lithium Could Be 2023's Next Big Surprise (Ad)
3 Undervalued Dividend Payers For Volatile Market Conditions
Here’s Why Viking Therapeutics Rose Over 50% on Obesity Drug Data
Lithium Could Be 2023's Next Big Surprise (Ad)
Roku And The 20% Rally That’s About To Start 
3 More Downgrades To Put On Your Buy List 
Nevada Could be the Source for America's Green Future (Ad)
The Bottom Is In For McCormick & Company
Buffett's company owns nearly 24% of Occidental Petroleum
NASDAQ:FGEN

FibroGen - FGEN Stock Forecast, Price & News

$18.81
+0.10 (+0.53%)
(As of 03/28/2023 12:00 AM ET)
Add
Compare
Today's Range
$18.64
$18.96
50-Day Range
$18.15
$25.18
52-Week Range
$7.81
$25.69
Volume
471,636 shs
Average Volume
1.03 million shs
Market Capitalization
$1.77 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$23.40

FibroGen MarketRank™ Forecast

Analyst Rating
Hold
2.40 Rating Score
Upside/​Downside
24.4% Upside
$23.40 Price Target
Short Interest
Bearish
5.55% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.84
Upright™ Environmental Score
News Sentiment
0.67mentions of FibroGen in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$2.06 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.75) to ($2.16) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.11 out of 5 stars

Medical Sector

488th out of 999 stocks

Pharmaceutical Preparations Industry

231st out of 489 stocks


FGEN stock logo

About FibroGen (NASDAQ:FGEN) Stock

FibroGen, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It focuses on the hypoxia-inducible factor and connective tissue growth factor biology to develop medicines for the treatment of anemia, fibrotic disease, and cancer. The company was founded by Thomas B. Neff on September 29, 1993 and is headquartered in San Francisco, CA.

Receive FGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for FibroGen and its competitors with MarketBeat's FREE daily newsletter.

FGEN Stock News Headlines

Why did Sarepta Therapeutics Stock Plummet? (FGEN)
SRPT stock fell 20% after the FDA changed course on their new DMD treatment approval. The stock remains strong with an encouraging outlook and a mod Buy rating.
Lithium Could Be 2023's Next Big Surprise
Lithium is the hottest commodity for our green future
Raymond James Reaffirms Their Buy Rating on FibroGen (FGEN)
FibroGen (FGEN) Reports Q4 Loss, Tops Revenue Estimates
Lithium Could Be 2023's Next Big Surprise
Lithium is the hottest commodity for our green future
Earnings Preview For FibroGen
Should You Buy FibroGen (FGEN) Ahead of Earnings?
FibroGen Third Quarter 2022 Earnings: Misses Expectations
FibroGen (FGEN) Reports Q3 Loss, Misses Revenue Estimates
FibroGen to Report Third Quarter 2022 Financial Results
FibroGen - Biotech - Seeking Alpha
FibroGen Reaches Analyst Target Price - Nasdaq
See More Headlines
Receive FGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for FibroGen and its competitors with MarketBeat's FREE daily newsletter.

FGEN Company Calendar

Last Earnings
2/27/2023
Today
3/29/2023
Next Earnings (Estimated)
5/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:FGEN
Employees
566
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$23.40
High Stock Price Forecast
$35.00
Low Stock Price Forecast
$14.00
Forecasted Upside/Downside
+24.4%
Consensus Rating
Hold
Rating Score (0-4)
2.40
Research Coverage
5 Analysts

Profitability

Net Income
$-293,650,000.00
Net Margins
-208.66%
Pretax Margin
-209.52%

Debt

Sales & Book Value

Annual Sales
$140.73 million
Book Value
($0.02) per share

Miscellaneous

Free Float
91,527,000
Market Cap
$1.77 billion
Optionable
Optionable
Beta
0.85

Key Executives

  • Enrique A. Conterno
    Chief Executive Officer & Director
  • Juan Graham
    Chief Financial Officer & Senior Vice President
  • Elias Kouchakji
    Senior VP-Clinical Development & Drug Safety
  • Mark Eisner
    Chief Medical Officer & Executive Vice President
  • John Hunter
    Chief Scientific Officer













FGEN Stock - Frequently Asked Questions

Should I buy or sell FibroGen stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for FibroGen in the last twelve months. There are currently 1 sell rating, 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" FGEN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FGEN, but not buy additional shares or sell existing shares.
View FGEN analyst ratings
or view top-rated stocks.

What is FibroGen's stock price forecast for 2023?

5 equities research analysts have issued twelve-month price targets for FibroGen's stock. Their FGEN share price forecasts range from $14.00 to $35.00. On average, they predict the company's stock price to reach $23.40 in the next twelve months. This suggests a possible upside of 24.4% from the stock's current price.
View analysts price targets for FGEN
or view top-rated stocks among Wall Street analysts.

How have FGEN shares performed in 2023?

FibroGen's stock was trading at $16.02 at the beginning of the year. Since then, FGEN stock has increased by 17.4% and is now trading at $18.81.
View the best growth stocks for 2023 here
.

Are investors shorting FibroGen?

FibroGen saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 4,830,000 shares, an increase of 20.1% from the February 28th total of 4,020,000 shares. Based on an average daily trading volume, of 929,100 shares, the days-to-cover ratio is presently 5.2 days. Approximately 5.6% of the company's shares are short sold.
View FibroGen's Short Interest
.

When is FibroGen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 8th 2023.
View our FGEN earnings forecast
.

How were FibroGen's earnings last quarter?

FibroGen, Inc. (NASDAQ:FGEN) announced its quarterly earnings data on Monday, February, 27th. The biopharmaceutical company reported ($0.70) earnings per share for the quarter, topping analysts' consensus estimates of ($0.95) by $0.25. The biopharmaceutical company earned $34.40 million during the quarter, compared to the consensus estimate of $23.95 million. FibroGen had a negative net margin of 208.66% and a negative trailing twelve-month return on equity of 338.94%. The company's revenue for the quarter was up 108.0% compared to the same quarter last year. During the same quarter last year, the firm posted ($1.45) earnings per share.

What other stocks do shareholders of FibroGen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other FibroGen investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Aegean Marine Petroleum Network (ANW), NIC (EGOV), Gran Tierra Energy (GTE), Allergan (AGN) and ALJ Regional (ALJJ).

When did FibroGen IPO?

(FGEN) raised $146 million in an initial public offering (IPO) on Friday, November 14th 2014. The company issued 8,100,000 shares at $18.00 per share. Goldman Sachs, Citigroup and Leerink Partners served as the underwriters for the IPO and RBC Capital Markets, Stifel and William Blair were co-managers.

What is FibroGen's stock symbol?

FibroGen trades on the NASDAQ under the ticker symbol "FGEN."

Who are FibroGen's major shareholders?

FibroGen's stock is owned by a number of institutional and retail investors. Top institutional investors include Armistice Capital LLC (4.11%), First Trust Advisors LP (3.17%), Schroder Investment Management Group (1.87%), Geode Capital Management LLC (1.76%), Price T Rowe Associates Inc. MD (0.99%) and Eagle Asset Management Inc. (0.96%). Insiders that own company stock include Christine Chung, Enrique A Conterno, Juan Graham, K Peony Yu, Kalevi Kurkijarvi, Mark Eisner, Pat Cotroneo, Thane Wettig and Thomas F Kearns Jr.
View institutional ownership trends
.

How do I buy shares of FibroGen?

Shares of FGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is FibroGen's stock price today?

One share of FGEN stock can currently be purchased for approximately $18.81.

How much money does FibroGen make?

FibroGen (NASDAQ:FGEN) has a market capitalization of $1.77 billion and generates $140.73 million in revenue each year. The biopharmaceutical company earns $-293,650,000.00 in net income (profit) each year or ($3.14) on an earnings per share basis.

How many employees does FibroGen have?

The company employs 566 workers across the globe.

How can I contact FibroGen?

FibroGen's mailing address is 409 ILLINOIS STREET, SAN FRANCISCO CA, 94158. The official website for the company is www.fibrogen.com. The biopharmaceutical company can be reached via phone at (415) 978-1200, via email at ir@fibrogen.com, or via fax at 415-978-1902.

This page (NASDAQ:FGEN) was last updated on 3/29/2023 by MarketBeat.com Staff